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Cardiac aldosterone production and ventricular remodeling. sion of specific mineralocorticoid receptors (MRs) also
An intracardiac production of aldosterone has been recently has been described in the heart of several species, includ-
reported in rat. This production is increased both acutely and ing humans, rabbit, and rat [4, 5], thus suggesting thatchronically by angiotensin II, observations suggesting that the
cardiac tissue may be a target for Aldo. This may explainheart contains a steroidogenic system that is regulated similarly
deleterious effects such as cardiac fibrosis that have beento the adrenal one. Cardiac production of aldosterone is small
compared with that of the adrenal, raising the question of its evidenced by several laboratories in experimental hyper-
function in normal conditions. Moreover, the regulation of this aldosteronism [6–8].
synthesis in pathophysiologic states remains unknown. In an The discovery of the production of Aldo in rat heartanalysis of the effects of a one-month myocardial infarction
brings a new step to the evolution of our ideas concerning(MI) on the cardiac steroidogenic system, it was observed that
the physiology of this hormone [9]. This demonstratesaldosterone-synthase mRNA and the aldosterone concentra-
tion were increased by 2- and 3.5-fold, respectively, in the the existence of an Aldo tissular system—that is, the
noninfarcted part of the rat left ventricle. MI also induced a presence in a cell or a group of cells of all the biochemical
1.9-fold increase in the cardiac angiotensin II level. Losartan elements necessary to hormone synthesis and of its spe-prevented these changes, and the MI-induced collagen deposi-
cific receptors—making a local autocrine or paracrinetion in noninfarcted area of the left ventricle was reduced by
action possible. Intervention of this Aldo from cardiac1.6- and 2.5-fold by both spironolactone and losartan treat-
ments, respectively. Thus, these observations indicate that MI origin in remodeling of the left ventricle in postinfarction
is associated with tissue-specific activation of myocardial aldo- has been evidenced very recently in the rat [10]. All of
sterone synthesis. This activation is mediated by cardiac angio- these observations reinforce the idea that mineralocorti-tensin II via the angiotensin II type 1 (AT1) receptor, and the
coids have functions, in physiologic as well as in patho-resultant increase of intracardiac aldosterone level may be
involved in post-MI ventricular remodeling. logic conditions, in cardiovascular tissue.
ALDOSTERONE IN THE HEART
Aldosterone (Aldo) plays a crucial role in sodium and
Synthesispotassium homeostasis of vertebrates by acting on epi-
thelial tissues, namely kidney and colon. However, sev- Glucocorticoids and mineralocorticoids (mainly Aldo)
eral clinical and experimental arguments indicate that are synthesized from cholesterol in adrenal cortex. The
Aldo may also modulate cardiovascular function. For two forms of the cytochrome P-450 enzyme that catalyze
example, an increase of plasma Aldo affects the left the final step of these synthetic pathways are encoded
ventricle geometry in primary aldosteronism [1]. Pre- by two closely related genes, CYP11B1 and CYP11B2,
viously, the multicenter CONSENSUS study demon- respectively, that display differences in their enzymatic
strated a relationship between the plasma Aldo concen- activity, regulation, and tissular distribution [11]. P-450
tration and mortality in patients with congestive heart 11b-hydroxylase (11b-OHase) synthesizes corticosterone
failure [2]. Using classic methods of physiology and phar- from deoxycorticosterone (DOC) in the zona fasciculata-
macology, several studies have shown that cardiovascu- reticularis and is mainly regulated by adrenocorticotropic
lar tone may be modified (generally increased) by miner- hormone (ACTH). P-450 aldosterone-synthase (Aldo-
alocorticoids and glucocorticoids [reviewed in 3]. The synthase) catalyzes synthesis of Aldo from DOC in the
mechanisms of their action remained, however, to be zona glomerulosa. Its activity is principally controlled by
determined. Besides brain and blood vessels, the expres- angiotensin II and potassium and more weakly by ACTH
and sodium (Fig. 1). Noticeably, Aldo-synthase and 11b-
OHase are mitochondrial enzymes and thus are highlyKey words: aldosterone, mineralocorticoid receptor, fibrosis, myocar-
dial infarct, heart. sensitive to the tissue oxygen concentration.
Our laboratory has shown that the main enzymes forÓ 2000 by the International Society of Nephrology
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Fig. 1. Synthesis of aldosterone (Aldo) and
its mode of action. The main steps of Aldo
biosynthesis are those known in adrenal gland.
It is likely that this scheme is also valid in
heart (discussed in the text). Angiotensin II
and potassium increase intracellular calcium
concentration (Ca21)i by different pathways,
whereas adrenocorticotropic hormone (ACTH)
increases cAMP. As a result, phosphoryla-
tion of cAMP response element-binding pro-
tein (CREB) allows its binding to the cAMP
response element (CRE) localized in the
CYP11B2 59 flanking region and activation of
Aldo-synthase gene transcription. The proxi-
mal CRE is not sufficient to support CYP11B2
expression, and other sequences are required
such as the orphan nuclear receptors steroido-
genic factor 1 (SF-1). Aldo acts in cells con-
taining the mineralocorticoid receptor (MR).
The NAD-dependent enzyme 11b-hydroxy-
steroid dehydrogenase 2 (11b-HSD2) inacti-
vates glucocorticoids and prevents their bind-
ing to MR. The presence of this enzyme into
cardiac cells that contain the MR is not firmly
established, and others mechanisms of miner-
alocorticoid selectivity are also likely opera-
tive in heart. Finally, the cardiac genes tran-
scribed after binding of MR to the hormone
response element (HRE) remain to be deter-
mined. Abbreviations are as follows: Em,
membrane potential; PLC, phospholipase C;
PKC, protein kinase C; PKA, protein kinase
A; PIP, phosphatidyl inositol diphosphate;
IP3, inositol triphosphate; CaMK, calmodulin
kinase; StAR, steroidogenic acute regulator.
Aldo biosynthesis are present in rat heart [11]. Quantita- ination by plasma steroids) using celite column chroma-
tography coupled to radioimmunoassay. Aldo is detectedtive reverse transcription-polymerase chain reaction
(RT-PCR) analysis evidences not only Aldo-synthase, in heart homogenate under baseline conditions, and its
level is markedly increased after three hours of perfusionbut also the 11b-OHase gene expression in atria and
ventricles of the young normal rat. Cardiac levels of 11b- by angiotensin II or ACTH. Interestingly, the Aldo con-
centration in myocardium is about 17-fold higher thanOHase mRNA are sevenfold higher than those of Aldo-
synthase mRNA. Interestingly, the 11b-OHase mRNA/ in plasma. Corticosterone is also present and increased
by angiotensin II or ACTH, whereas the common pre-Aldo-synthase mRNA ratio is identical in adrenals and
in heart. The total amount of both mRNA molecules in cursor DOC is decreased in parallel. Additional experi-
ments aimed to study the chronic regulation of this car-whole heart is only 100-fold lower than in adrenal glands.
To ascertain whether the steroid synthesis pathway is diac steroidogenic system have shown that it behaves in
a very similar way to that of the adrenal gland. The Aldofunctional, Aldo and corticosterone production have
been measured in the isolated rat heart (to avoid contam- synthesis pathway is sensitive to a low-sodium/high-
Delcayre et al: Cardiac Aldo and ventricular remodeling1348
potassium diet and to angiotensin II, whereas the cortico- mology of their DNA binding site, MR and GR bind to
common nuclear glucocorticoid response elementssterone synthesis pathway responds positively to angio-
tensin II and ACTH. Thus, it is likely that Aldo synthesis (GREs). The regulation of transcription is also depen-
dent on an interaction with the transcription initiationin the heart is controlled by pathways similar to those
described in adreno-cortical cells, as depicted in Figure 1. complex and on diverse intracellular signaling pathways
[21]. In addition, increasing evidence indicates the exis-Extra-adrenal sites of steroid hormone production
have also been identified in peripheric vessels. Indeed, tence of coactivators and corepressors acting as a bridg-
ing factor between activated receptor and transcriptionAldo and corticosterone production and 11b-OHase and
Aldo-synthase gene expression have been demonstrated initiation complex [22, 23]. MR is thus able to bind spe-
cific DNA sequences and to regulate the expression ofin mesenteric rat artery and in endothelial and smooth
muscle cells isolated from human pulmonary artery Aldo-responsive genes, like Na1,K1-ATPase in kidney
[24]. In heart, however, Aldo target genes are not fully[12–14]. Moreover, these authors have shown that this
vascular Aldo potentiates angiotensin II-induced hyper- elucidated.
It should also be pointed out that rapid (2 to 10 min)trophy of cultured vascular smooth muscle cells, sug-
gesting a physiologic role for this locally generated ste- effects of Aldo have been described. These effects, not
inhibited by spironolactone, are presumably mediatedroid [12].
by a yet unknown membrane receptor and do not involve
Mode of action protein synthesis. They may have physiopathologic con-
sequences, since a study from Wehling’s laboratory per-Whatever its origin, plasmatic or tissular, Aldo has
effects in heart because of the presence of its MR in formed in patients during cardiac catheterization de-
scribes rapid changes of systemic vascular resistance andcardiomyocytes and in the endothelial wall of main coro-
nary arteries [5]. The intracellular MR is a transcription cardiac output 10 minutes after Aldo infusion [25].
factor and forms a subfamily with glucocorticoid recep-
tors (GRs), progesterone, and androgen receptors. In
ALDOSTERONE AND CARDIAC REMODELING
addition to epithelial tissues (as kidney, parotid gland,
Cardiac fibrosisand colon), both the mRNA and protein MR have also
been found in rodent and human hearts [5, 15, 16]. In One of the best documented effects of Aldo on the
heart is the induction of an important fibrosis, with detri-the heart, in situ hybridization indicates that MR is ex-
pressed in cardiomyocytes, endothelial cells, and fibro- mental consequence for the cardiac pump. Karl Weber’s
group has found that fibrosis appears in rat heart onlyblasts [15].
The high amino acid sequence identity in the ligand- if Aldo and sodium intake are chronically increased [6].
The role of sodium in the pathogenesis of fibrosis isbinding domains of MR and GR leads to substantial
binding of glucocorticoids to MR. As circulating concen- crucial but still unresolved [26]. To confirm the specific
effect of the hormone, it has been shown that inhibitiontrations of glucocorticoids are commonly three orders
of magnitude higher than those of Aldo, it is important of Aldo binding to MR by a low dose of spironolactone
prevents only fibrosis, but not the associated hyperten-to determine how Aldo may exert a specific action. This
is achieved by two means: (1) The NAD-dependent en- sion and left ventricle hypertrophy, whereas a high dose
prevents all secondary effects of the treatment [27].zyme 11b-hydroxysteroid dehydrogenase II (11b-HSD
II) converts cortisol and corticosterone into cortisone Whereas the increase in hypertrophy and atrial natri-
uretic peptide mRNA are restricted to the left ventricle,and 11-dehydrocorticosterone, respectively, which have
negligible affinity for MR. (2) MR may also discriminate fibrosis appears in both ventricles [6–8], supporting the
contention that this Aldo-induced cardiac response isAldo from glucocorticoids independently of 11b-HSD
II. Indeed, the off-rate of Aldo from MR is five times independent of hemodynamic factors.
One characteristic feature of this experimental modellower than that of glucocorticoids, despite similar-affinity
constants [17]. These have been described in kidney and of hypertension is the long interval of time observed
between the increase of plasma Aldo (obtained by os-also seem to be operative in heart, since the 11b-HSD
II is coexpressed with MR in human and rat hearts, with, motic minipumps) and the modifications of cardiac struc-
ture [28]. Indeed, types I and III procollagen increasehowever, a low activity [17–19].
Binding of Aldo induces dissociation of chaperone in both ventricles at two weeks only, whereas progressive
cardiac fibrosis is found at one month. At two months,proteins (which maintain the receptors inactive) and ex-
position of nuclear localization signals in MR. In the total MatrixMetalloProtease-2 activity is increased and
localized by in situ zymography within the media of coro-absence of hormone, MR is present in both cytoplasm
and nucleus, whereas in the presence of Aldo, activated nary arteries, suggesting a role in vascular remodeling
[29]. Thus, cardiac alterations are late, precluding a directMR rapidly accumulates in dynamic clusters in the cell
nucleus [20]. In agreement with the high degree of ho- modulation of cardiac collagen synthesis by Aldo in vivo.
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The early mechanisms by which Aldo induces fibrosis in the noninfarcted zone of left ventricle. Since the
are far from being understood. Recent results from our plasma Aldo concentration is unchanged and the cardiac
laboratory show that cardiac angiotensin II receptor may Aldo production is increased, it can be concluded that
be a target for Aldo, suggesting a potentiation of fibro- the effect of spironolactone on the cardiac collagen con-
genic properties of angiotensin II. Indeed, ventricular tent is only due to the blockade of cardiac Aldo. Thus,
density of AT1 receptors is 1.5-fold increased in rats the selective activation of cardiac Aldo synthesis is in-
treated one month with Aldo-salt, this increase being volved in the ventricular remodeling secondary to MI.
prevented by both spironolactone and losartan [30]. Ad-
ditionally, a series of observations based on selective
inhibition of different effectors has been made in Aldo- FUNCTIONS OF CARDIAC ALDOSTERONE
salt or deoxycorticosterone-salt excess, suggesting the The results mentioned earlier in this article indicate
involvement of other agents like calcium, bradykinin, that the heart is equipped with a functional system of
endothelin, and possibly nitric oxide [reviewed in 31]. Aldo synthesis and that its activation in pathological
conditions may influence the cardiac structure and/orRole in the ventricular remodeling of postinfarction
function. These observations raise the question of thePrevious observations suggest that an elevation of the
potential role of such a system (which also produceslevel of angiotensin II in heart may induce an elevation
glucocorticoids) in normal conditions. This question isof the level of Aldo [9]. This could happen in pathological
related to the general problem of the local hormonalsituations in which such an increase of tissular angioten-
systems now identified in cardiac or vascular tissue, suchsin II has been evidenced, such as the myocardial in-
as the renin-angiotensin and adrenergic systems. Thefarction (MI). To verify this hypothesis and to evaluate
possibility of autocrine or paracrine effects in myocar-its consequences, concentrations of angiotensin II and
dium has been a matter of controversy, and this contro-of Aldo were measured in the left ventricle one month
versy has lasted for about 10 years in the case of theafter an experimental MI in rats [10]. Seven days after
intracardiac renin-angiotensin system. As it is the casesurgery, rats were randomized in three groups: MI, MI 1
for the cardiac steroidogenic system [9], the cardiac renin-spironolactone (20 mg/kg/day), and MI 1 losartan (8 mg/
angiotensin system generates tissular concentrations ofkg/day). Cardiac function was not altered one month
angiotensin II that are far higher (10- to 20-fold) thanafter MI, and left ventricular hypertrophy was prevented
those measured in plasma [10, 32]. The high Aldo con-only by losartan treatment. At this time point, Aldo-
synthase mRNA is increased by 100%, Aldo concentra- centration in heart (relative to that of plasma) supports
tion by 267%, and angiotensin II concentration by 90% a putative physiological role. Such a role is yet not
in the noninfarcted part of left ventricle (Fig. 2). These known. As suggested by several studies, cardiac Aldo
variations are prevented by losartan, not by spironolac- may be involved in the control of ionic movements [33,
tone. Plasma concentrations of aldo are unchanged what- 34]. Angiotensin II and Aldo may have interactions in
ever the treatment. The MI-induced increase in left ven- myocardium, as already mentioned since Ang II en-
tricular collagen is decreased 1.6- and 2.5-fold by hances cardiac Aldo synthesis. On the other hand, Aldo
spironolactone and losartan, respectively. Whereas the increases AT-1 receptor mRNA and density [28, 35] and
left ventricular norepinephrine concentration is not potentiates angiotensin II-stimulated hypertrophy [12].
modified by MI, both spironolactone and losartan de- These actions may thus sensitize cardiac responses to
crease this value by 50%. circulating or locally produced angiotensin II. Finally, as
Postinfarction thus involves a selective activation of detailed in this article, cardiac Aldo is involved in cardiac
the Aldo cardiac synthesis pathway (Fig. 3). This activa-
remodeling and in the generation of ventricular arrhyth-
tion is at the expense of cardiac corticosterone produc-
mia through the control of norepinephrine uptake [36].tion. These cardiac regulations are prevented by an AT1
Identification of the site of synthesis could also giveantagonist. However, the plasmatic renin-angiotensin
useful information. Indeed, if the site of synthesis ofsystem is not activated one month after MI. In contrast,
these cardiac hormones is close to the site of action (andthe cardiac angiotensin II level is increased. Thus, the
a comparative study of the localization of biosynthesisstimulus that increases the cardiac production of Aldo
enzymes and of receptors would allow this question towould be the tissular increase of angiotensin II that is
be answered), the response of such a local system isevidenced in MI. This experimental model allows a selec-
necessarily very short. One may thus think that a hor-tive approach to dissociate the action of cardiac Aldo
monal system with rapid adaptation is able to modulatefrom that of plasmatic Aldo. Indeed, in contrast to the
on the short term the properties of a group of cells,cardiac system, the adrenal steroidogenic system is not
thus ensuring a fine tuning relative to the influence ofactivated one month after MI. Spironolactone does not
prevent the myocyte hypertrophy, but decreases fibrosis circulating hormones.
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Fig. 2. Effect of myocardial infarction on
ventricular aldosterone, angiotensin II, and
left ventricular fibrosis. Seven days after an
experimental myocardial infarct, rats were
treated by 20 mg/kg/day of spironolactone or
8 mg/kg/day of losartan for 25 days. Concen-
trations of hormones, Aldo-synthase mRNA,
and collagen are measured in the noninfarcted
zone of left ventricle.
Fig. 3. Changes of cardiac aldosterone and
glucocorticoids biosynthesis pathways after
myocardial infarction. Cardiac production of
Aldo is increased, and that of corticosterone
is decreased in parallel after an experimental
myocardial infarction. This increase is the re-
sult of increased cardiac angiotensin II via its
AT1 receptor. It participates to the develop-
ment of fibrosis in the noninfarcted zone of
left ventricle.
CONCLUSION tant in diverse pathologic situations, as shown in the MI
study. The intracellular localization, the role(s) and theDiscovery of tissular hormonal systems has suggested
regulations in physiopathologic models of this new car-that they have local regulatory roles that are more or
diac steroidogenic system are major research directionsless independent from circulating hormones. The obser-
to expand our understanding of local hormonal systems.vations discussed here raise the possibility of interactions
Transgenic technology is one of the possible ways tobetween local systems, since local variations of angioten-
gain further insight into this matter. Additionally, it issin II may modify the cardiac concentration of Aldo.
The consequences of such changes are likely to be impor- important to note that the observations described earlier
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